Abstract
Human hepatitis B virus (HBV) causes chronic hepatitis disease which is a major public health problem worldwide. HBV has 4 genes encoding viral DNA polymerase, protein X and two structural proteins, the surface and core proteins. HBV DNA polymerase has been a primary target for the development of anti-HBV agents due to its enzymatic nature, and several nucleoside derivatives that inhibit HBV polymerase are currently used as anti-HBV therapeutics. On the other hand, accumulating information on the capsid assembly and the maturation process of HBV particles provides additional approaches for the development of anti-HBV agents. Proper interaction between core proteins is required for assembly of the nucleocapsid, and the specificity of the interactions between the capsid and surface proteins is essential for the maturation of active HBV in infected cells. In this article, the assembly process of active HBV particles and approaches to utilize the interactions of HBV structural proteins as target site for the development of anti-HBV agents are reviewed. In particular, novel approaches to target the assembly process and the interaction between HBV structural proteins are introduced.
Keywords: HBV, core protein, surface protein, capsid assembly, assembly inhibitor
Infectious Disorders - Drug Targets
Title: Interaction and Assembly of HBV Structural Proteins: Novel Target Sites of Anti-HBV Agents
Volume: 7 Issue: 3
Author(s): In-Geol Choi and Yeon Gyu Yu
Affiliation:
Keywords: HBV, core protein, surface protein, capsid assembly, assembly inhibitor
Abstract: Human hepatitis B virus (HBV) causes chronic hepatitis disease which is a major public health problem worldwide. HBV has 4 genes encoding viral DNA polymerase, protein X and two structural proteins, the surface and core proteins. HBV DNA polymerase has been a primary target for the development of anti-HBV agents due to its enzymatic nature, and several nucleoside derivatives that inhibit HBV polymerase are currently used as anti-HBV therapeutics. On the other hand, accumulating information on the capsid assembly and the maturation process of HBV particles provides additional approaches for the development of anti-HBV agents. Proper interaction between core proteins is required for assembly of the nucleocapsid, and the specificity of the interactions between the capsid and surface proteins is essential for the maturation of active HBV in infected cells. In this article, the assembly process of active HBV particles and approaches to utilize the interactions of HBV structural proteins as target site for the development of anti-HBV agents are reviewed. In particular, novel approaches to target the assembly process and the interaction between HBV structural proteins are introduced.
Export Options
About this article
Cite this article as:
Choi In-Geol and Yu Gyu Yeon, Interaction and Assembly of HBV Structural Proteins: Novel Target Sites of Anti-HBV Agents, Infectious Disorders - Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/187152607782110077
DOI https://dx.doi.org/10.2174/187152607782110077 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Kinetoplast as a Potential Chemotherapeutic Target of Trypanosomatids
Current Pharmaceutical Design Neuroproteomics and the Detection of Regulatory Phosphosites
Current Proteomics Emerging Therapies in Chronic Myeloid Leukemia
Current Cancer Drug Targets The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Anti-metastatic Treatment in Colorectal Cancer: Targeting Signaling Pathways
Current Pharmaceutical Design Pyrazole Substituted 9-Anilinoacridines as HER2 Inhibitors Targeting Breast Cancer - An <i>in-silico</i> approach
Current Drug Research Reviews Established and In-trial GPCR Families in Clinical Trials: A Review for Target Selection
Current Drug Targets Evolution and Pathogenesis of Oncoviruses Associated with Head and Neck Cancer: History and Current Concepts
Recent Patents on Biomarkers A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Electrotransfer into Skeletal Muscle for Protein Expression
Current Gene Therapy Anti-Invasive and Anti-Metastasis Strategies: New Roads, New Tools and New Hopes
Current Cancer Drug Targets Effect of Flavonoids on Human Health: Old Subjects but New Challenges
Recent Patents on Biotechnology Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy A Recent Update on the Role of Ghrelin in Glucose Homeostasis
Current Diabetes Reviews The Molecular Basis of Notch Signaling Regulation: A Complex Simplicity
Current Molecular Medicine Morphological and Functional Characteristic of Senescent Cancer Cells
Current Drug Targets Challenges in the Design of Clinically Useful Brain-targeted Drug Nanocarriers
Current Medicinal Chemistry Endothelial Endocytic Pathways: Gates for Vascular Drug Delivery
Current Vascular Pharmacology Topical Therapies for Oral Lichen Planus Management and their Efficacy: A Narrative Review
Current Pharmaceutical Design